date:May 10, 2012
ients and its therapeutic indications. Well amend the filing when the results of the study are in.
Human clinical trial just starting
The primary endpoints of the 30-day study, which is being conducted at Pennington Biomedical Research Center, Louisiana, will be insulin sensitivity, blood glucose levels and alterations in the gut flora, he said.
Well look at secondary endpoints like hunger and body weight because the ingredients were using are known to regulate gut hormones associated with